| dc.creator |
Bezabih, Mintewab |
|
| dc.creator |
Stolpe, Michael |
|
| dc.date |
2007 |
|
| dc.date.accessioned |
2013-10-16T06:20:19Z |
|
| dc.date.available |
2013-10-16T06:20:19Z |
|
| dc.date.issued |
2013-10-16 |
|
| dc.identifier |
http://hdl.handle.net/10419/4239 |
|
| dc.identifier |
ppn:560065523 |
|
| dc.identifier.uri |
http://koha.mediu.edu.my:8181/xmlui/handle/10419/4239 |
|
| dc.description |
This paper develops a real options approach to the optimal sequencing of antiretroviral drug cocktails for HIV/AIDS patients in resource-poor settings. The analysis focuses on the implications of endogenous resistance mutations in the virus that reduce or eliminate the effectiveness of individual drugs within a cocktail when lack of laboratory equipment prevents these from being identified. Using a model with two drug cocktails, we show that the first-line therapy should be introduced later than in the case without resistance mutations and that the second-line therapy should be introduced earlier. We go on to discuss implications for comparative cost-effectiveness analyses. |
|
| dc.language |
eng |
|
| dc.publisher |
Kiel Institute for the World Economy (IfW) Kiel |
|
| dc.relation |
Kieler Arbeitspapiere 1371 |
|
| dc.rights |
http://www.econstor.eu/dspace/Nutzungsbedingungen |
|
| dc.subject |
D81 |
|
| dc.subject |
H51 |
|
| dc.subject |
I12 |
|
| dc.subject |
ddc:330 |
|
| dc.subject |
HIV/AIDS |
|
| dc.subject |
Real option theory |
|
| dc.subject |
Cost-effectiveness analysis |
|
| dc.subject |
Combination therapy |
|
| dc.subject |
Developing countries |
|
| dc.subject |
AIDS |
|
| dc.subject |
Pharmazeutisches Produkt |
|
| dc.subject |
Kosten-Wirksamkeits-Analyse |
|
| dc.subject |
Realoption |
|
| dc.subject |
Entwicklungsländer |
|
| dc.title |
Optimal sequencing of antiretroviral drug cocktails under uncertainty and irreversibility |
|
| dc.type |
doc-type:workingPaper |
|